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A B S T R A C T
Context and objective: Incidence of prostate cancer (PC) is increasing, but androgen deprivation therapy (ADT)
and other therapies are substantially improving survival. In this context, careful consideration of skeletal health
is required to reduce the risk of treatment-related fragility fractures and their associated morbidity and mor-
tality. This risk is currently not well-managed. ADT causes significant loss of bone mineral density (BMD). In the
metastatic setting, systemic treatments (e.g. chemotherapy, abiraterone, enzalutamide) are used alongside ADT
and may require concomitant glucocorticoids. Both ADT and glucocorticoids pose significant challenges to
skeletal health in a population of patients already likely to have ongoing age-related bone loss and/or comorbid
conditions. Current PC guidelines lack specific recommendations for optimising bone health. This guidance
presents evidence for assessment and management of bone health in this population, with specific re-
commendations for clinical practitioners in day-to-day PC management.
Methods: Structured meetings of key opinion leaders were integrated with a systematic literature review. Input
and endorsement was sought from patients, nursing representatives and specialist societies.
Summary of guidance: All men starting or continuing long-term ADT should receive lifestyle advice regarding
bone health. Calcium/vitamin D supplementation should be offered if required. Fracture risk should be calcu-
lated (using the FRAX® tool), with BMD assessment included where feasible. BMD should always be assessed
where fracture risk calculated using FRAX® alone is close to the intervention threshold. Intervention should be
provided if indicated by local or national guidelines e.g. UK National Osteoporosis Guideline Group (NOGG)
thresholds. Men requiring bone protection therapy should be further assessed (e.g. renal function), with referral
to specialist centres if available and offered appropriate treatment to reduce fracture risk. Those near to, but
below an intervention threshold, and patients going on to additional systemic therapies (particularly those re-
quiring glucocorticoids), should have FRAX® (including BMD) repeated after 12–18 months.
Patient summary: Modern treatments for prostate cancer have led to significant improvements in survival and
quality of life. However, some of these treatments may lead to weakening of patient’s bones with risk of fracture
and it is therefore important to monitor patients’ bone health and provide bone protection where needed. This
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paper provides specific guidance to clinical teams, based on the most recent research evidence, to ensure optimal
bone health in their patients.
1. Introduction
Bone health is emerging as one of the most important considerations
for men receiving treatment for prostate cancer (PC). Projected to be
the commonest cancer by 2030, 1 in 8 men will receive a diagnosis of
PC in their lifetime. There are more than 400,000 new cases of PC in
Europe each year. Despite the fact that PC is the second leading cause of
cancer-related mortality in men [1], survival rates have improved
considerably over the past four decades as a result of both earlier di-
agnosis and newer therapies (current 5-year survival is 85% in all pa-
tients, compared with 71% in 1980) [2].
As a result, many patients with PC now live with their disease for
many years, and consideration of the long-term consequences of
treatment is of increasing importance. Men with PC are not routinely
referred to bone specialists for optimisation of their bone health, de-
spite the fact that cancer treatment induced bone loss (CTIBL) and the
resulting increased risks of fragility fractures (often requiring hospita-
lisation) represent substantial problems for patients and healthcare
systems [3], in addition to those posed by pathological fractures in men
with metastatic bone involvement [4]. New PC therapies, whilst im-
proving survival, often add to this risk [5]. There is an urgent need for
increased focus on these issues. This guidance aims to provide non-bone
specialists with evidence-based recommendations to support the as-
sessment and management of bone health in men receiving PC treat-
ment.
2. Methodology
2.1. Expert group and specialist society involvement
This guidance was developed by a group of key opinion leaders in
the management of PC and bone disorders. The group included medical
and clinical oncologists, urologists, endocrinologists, rheumatologists,
metabolic bone disease specialists, general practitioners and uro-on-
cology nurse specialists, with input from patient representatives. Input/
endorsement was also sought from specialist societies (see acknowl-
edgements).
2.2. Current guidelines
Current national and international guidelines lack detailed, re-
commendations developed specifically for managing CTIBL in men re-
ceiving treatment for PC. The UK National Institute for Health and Care
Excellence (NICE) Clinical Guideline makes only general re-
commendations; that fracture risk is considered for all men receiving
ADT and that treatment is offered to all those with osteoporosis [6].
Joint European Association of Urology, European Society for Radio-
therapy and Oncology (ESTRO) and International Society for Geriatric
Oncology (SIOG) PC guidelines suggest that BMD assessment is un-
dertaken prior to the initiation of long-term ADT, and that the FRAX®
tool should be used to estimate individual fracture risk [7]. Recent
ASCO guidance is based on endorsement of a 2017 Cancer Care Ontario
Programme [8] and Guidance from the National Comprehensive Cancer
Network (NCCN) recommends screening and treatment for osteoporosis
according to guidelines for the general population from the National
Osteoporosis Foundation [9].
There is no current guidance as to the intervention thresholds that
should be used to initiate treatment, or the most appropriate pharma-
cological therapy. It is often unclear who should have overall respon-
sibility for managing bone health in PC patients, many of whom will be
managed in a multi-disciplinary setting across both primary and sec-
ondary care.
2.3. Definition of scope
The scope of the guidance was defined as follows:
• To address the need for specific guidance for the management of
CTIBL in PC (including intervention thresholds) in a European set-
ting
• To summarise the evidence supporting the management of bone
health during PC treatment for non-bone specialists (including
general practitioners, urologists, oncologists and specialist nurses)
involved in the care of patients with PC at risk of CTIBL.
• Using the UK as an exemplar, to sit the PC guidance alongside the
NICE-accredited National Osteoporosis Guidance Group Clinical
Guideline (2017) for the prevention and treatment of osteoporosis
and the NICE guidance for the diagnosis and management of pros-
tate cancer (NICE Clinical Guideline 175).
2.4. Search strategy and selection of evidence
A literature search was undertaken using PubMed and Ovid
MEDLINE databases for relevant peer-reviewed articles published in
English between January 2000 and July 2019. Randomised controlled
trials, observational studies and meta-analyses were included. Search
terms included prostate cancer, prostate carcinoma and prostate ade-
nocarcinoma, and were mapped to the following subject headings for
bone; bone health, bone density, bone mineral density, osteoporosis,
osteopenia, bone turnover markers, bone biomarkers, fracture, skeletal
related event, bisphosphonates, denosumab and exercise. For ADT,
prostate cancer was used to search in combination with ADT, androgen
deprivation therapy, androgen suppression, hormone therapy, GnRH
agonist, luteinising hormone releasing hormone antagonist, and anti-
androgens.
Abstracts were screened for relevance by at least two members of
the expert reference group, with any disagreement resolved by con-
sensus after discussion.
3. Prostate cancer and bone loss
3.1. Androgen deprivation therapy (ADT)
ADT is offered to men with PC in several different clinical settings,
including: men who present with or progress to metastatic disease
(continuous ADT); men who receive radical radiotherapy for localised
or locally advanced disease (temporary ADT); and men who progress
during a period of watchful waiting who are not fit for radical treatment
(palliative continuous ADT). These indications are based upon clear
evidence from large randomised clinical trials [10–13]. ADT may also
be administered intermittently [14].
ADT is most commonly achieved by the administration of lutei-
nising hormone releasing hormone (LHRH) agonists (such as goserelin
and leuprorelin) and LHRH antagonists (such as degarelix). ADT causes
a rapid and substantial reduction in circulating androgens and oestro-
gens, disrupting bone remodelling balance, stimulating osteoclast ac-
tivity, decreasing osteoclast apoptosis, and increasing apoptosis of os-
teoblasts, all of which lead to net bone loss [15].
Even before ADT is initiated, PC patients may have lower baseline
BMD than age-matched controls [16]. Prospective studies found that
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loss of BMD is most rapid during the first year of ADT (5–10% BMD
loss) [17,18] and is greater than both normal age-related bone loss
(0.5–1.0% per annum) and bone loss during menopause. Bone loss, as
well as disruption to bone microarchitecture [19] continues throughout
the duration of ADT and ongoing CTIBL in men with PC is super-
imposed upon normal age-related bone loss (more than half of men
diagnosed with PC are aged over 70 years). It is likely that older men
will also have risk factors for fragility fracture other than ADT, such as
risk of falls and comorbid conditions.
ADT also affects body composition. Adiposity is substantially in-
creased along with a decrease in lean body mass within 3–12 months of
ADT initiation [20]. ADT-induced sarcopenia, defined as a progressive
impairment of muscle function due to loss of skeletal muscle mass,
increases the risk of falls, fractures and consequent loss of function or
independence [18].
3.2. Chemotherapy
The STAMPEDE and CHAARTED trials have demonstrated survival
benefit when chemotherapy is given upfront alongside ADT in men with
metastatic hormone-sensitive PC [21,22]. Men in this situation who are
fit enough are currently offered six cycles of docetaxel. In the STAM-
PEDE study, glucocorticoids were given alongside each cycle of doc-
etaxel as pre-medication (dexamethasone) and as a daily dose of pre-
dnisolone (10 mg per day) throughout the treatment period of up to
18 weeks. In many (but not all) centres, this glucocorticoid regime is
now adopted as standard of care, further challenging bone health.
3.3. Other systemic therapies
Abiraterone acetate is a selective androgen synthesis inhibitor
which blocks androgen production in the testes, adrenals and prostate
tumour tissue. It is recommended for use in men with metastatic cas-
tration resistant prostate cancer (mCRPC) [23] and has also been found
to improve survival in men with newly diagnosed hormone-sensitive
metastatic PC (compared to ADT alone) [24,25]. It is currently ap-
proved in the USA, and recommended by ESMO and EAU for use in this
setting [26]. As abiraterone also blocks the production of glucocorti-
coids, prednisolone (usual dose 10 mg/day) is given together with
abiraterone, and may further challenge bone health.
Enzalutamide is an oral androgen receptor inhibitor that is currently
used in men with mCRPC [27], which does not require concomitant
glucocorticoids. Enzalutamide may also have a role in the management
of non-metastatic CRPC [28] and also in metastatic castrate sensitive
disease [29]. Other anti-androgen agents are in development or newly-
approved (eg darolutamide [30] and apalutamide [31]) with currently
unknown effects on fracture rate and assessment of bone health will be
of growing and continuing importance. Radium-223 monotherapy,
given IV, is widely used for treatment of mCRPC which has metastasised
only to the skeleton, following trials which showed an overall survival
benefit of 3.6 months [32] and a reduced risk of symptomatic skeletal
related events (SSREs) [33]. However, in the REASURE trial, new
fractures were commonly seen on imaging in men with mCRPC during
and after treatment with Ra-223 monotherapy [34] and, when radium-
223 is used in combination with other agents, increased fracture risk
has been observed as reported in a combination study where the ad-
dition of radium-223 to abiraterone acetate plus prednisone or pre-
dnisolone did not improve SSRE-free survival in patients with castra-
tion-resistant prostate cancer and bone metastases, and was associated
with an increased frequency of bone fractures compared with placebo
[5].
Interim data from the ongoing EORTC1333/PEACEIII study, showed
that addition of radium-223 to enzalutamide increased the 1-year cu-
mulative fracture rate from 12.4% (already significant with en-
zalutamide alone) to 27.4%, but remarkably no fractures occurred
when patients started treatment with a bone-protecting agent at least
6 weeks before radium-223 administration [35]. These are interim data,
but they dramatically illustrate the importance of considering bone
protection and following appropriate guidance. When full data become
available, they may well justify all such mCRPC patients routinely re-
ceiving bone protection. In patients with bone metastases from CRPC at
high risk for clinically significant SREs, ESMO guidelines recommend
denosumab or zoledronate at doses higher than those required for
protection against CTIBL alone.
4. Glucocorticoids and bone loss
The long-term use of glucocorticoids is the commonest cause of
iatrogenic osteoporosis and one of the commonest causes of secondary
osteoporosis. As a consequence of increased bone resorption, decreased
formation and interruption of regulatory pathways, there is an early
and rapid loss of BMD and bone quality. The risk of hip and vertebral
fractures increases up to 7- and 17-fold respectively when doses
equivalent to 10–12 mg prednisolone are given for more than 3 months
[36]. There is a need for further studies to investigate the impact of the
combination of docetaxel and glucocorticoids on bone health and risk
of fracture in men with PC.
5. Osteoporosis
Osteoporosis is a progressive systemic skeletal disorder, char-
acterised by low bone mass and microarchitectural deterioration of
bone tissue, with a consequent increase in bone fragility and suscept-
ibility to fracture [37]. Its prevalence increases with age, due to both
age-related loss of BMD (0.5–1.0% per year) and the presence of factors
that accelerate bone loss, such as the menopause, lifestyle factors,
presence of comorbid conditions and use of medications affecting bone.
The World Health Organization (WHO) definition of osteoporosis, is
based upon BMD. Using dual energy X-ray absorptiometry (DXA), a
BMD T-score of 2.5 SD or more below the mean value for young healthy
adults is diagnostic of osteoporosis [38]. The proximal femur (total hip
or femoral neck) is an important site to assess due to its higher pre-
dictive risk for hip fracture. Measurement of lumbar spine (LS) BMD
should also be considered in all patients, though the presence of de-
generative changes, vascular calcification and fractures may affect in-
terpretation of the result. In Europe, there are 22 million women and
5.5 million men living with osteoporosis, which is responsible for 3.5
million fragility fractures per year. The economic burden of both in-
cident and prior fragility fractures has been estimated at €37 billion
[39].
Fragility fractures arise as a consequence of low energy mechanical
forces that would not ordinarily cause fracture (equivalent to a fall from
standing height or less), and most commonly affect the proximal femur
(hip), vertebrae and distal radius [40]. Hip fractures, in particular, pose
a considerable challenge to health and social care provision. Significant
morbidity arises from the consequent pain, disability and loss of in-
dependence, with over 50% of patients unable to live independently,
and only 30% recovering fully. The association between hip fracture
and mortality is well established, with around one third of patients
dying within 12 months [41]. Importantly, mortality following hip
fracture is significantly higher in men [42].
Several other factors that are BMD-independent may also contribute
to fracture risk including; age, sex, increased risk of falls, previous
fracture, family history of fracture, and other lifestyle factors. Fracture
risk assessment tools such as FRAX® and QFracture have been devel-
oped, to integrate these variables with other information in order to
better determine the risk of fracture.
A range of bone turnover markers (BTMs), mostly related to col-
lagen metabolism, can be measured in urine or serum, to indicate the
status of bone formation and bone resorption. While not used widely in
clinical practice, they may be particularly useful in monitoring the re-
sponse of bone turnover to pharmacological treatments [43].
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Table 1
Randomised studies of the effect of bisphosphonates and denosumab in men receiving ADT for Prostate Cancer.
Year Study population N Study groups Follow-up Key findings
2001 [56] Locally advanced or recurrent PC 47 Pamidronate + ADT vs ADT only 48 weeks No significant BMD change in pamidronate group
Significant loss of BMD at LS and hip in ADT only group (−3.3% and −1.8%, p < 0.001)
2001 [57] Metastatic PC 21 MAB + pamidronate vs MAB 12 months Significant increase in LS (+7.8% vs −5.7% p = 0.0001) and femoral neck (+2.0% vs −2.3%
p = 0.0007) BMD in pamidronate group compared to MAB group
2003 [58] Non-metastatic PC 106 Zoledronic acid + ADT vs ADT 12 months Zoledronic acid associated with increased LS BMD compared to ADT alone (5.6% Vs −2.2%,
p < 0.001)
2005 [59] Locally advanced PC, OP at baseline 60 MAB vs MAB + neridronic acid vs bicalutamide vs
bicalutamide + neridronic acid
12 months MAB group experienced significant BMD loss at LS and hip (−4.9% and −1.9%; p = 0.002 and
0.004 respectively)
No BMD change in the MAB and neridronic acid group
Non-significant BMD loss in bicalutamide groupBMD increase at LS (+2.5%; p < 0.05) and hip
(+1.6%; p < 0.05) in bicalutamide + neridronic acid group
2006 [60] Non metastatic PC and received
ADT <12 months
120 Zoledronic acid + ADT vs placebo + ADT 12 months Increase in LS and hip BMD in zoledronic acid group compared with placebo (p < 0.0001 for both)
2007 [61] Localised and metastatic PC
receiving ADT <12 months
42 Zoledronic acid + ADT vs placebo + ADT 12 months Increase in LS (+4.9% vs −2.2% p < 0.0001) and femoral neck (0.9% vs −3.2% p < 0.0001)
BMD in zoledronic acid group compared with placebo
2007/8 [62,63] Non-metastatic PC 112 Alendronic acid + ADT vs
placebo + ADT
(crossover at 12 months)
24 months BMD increased at LS and hip with alendronic acid, and decreased with placebo (p < 0.001) at
1 year
At crossover, significant LS and hip BMD gains continued during second year of alendronic
acid.BMD maintained at hip and spine in those who switched to placebo, but BMD loss at radius.
2007 [64] Non-metastatic PC receiving ADT 44 Zoledronic acid + ADT vs placebo + ADT 12 months Increase in hip (+4.0% vs −3.1% p < 0.001) and LS (+0.7% vs −1.9% p = 0.004) BMD with
zoledronic acid compared with placebo
2009 [65] Non metastatic PC initiating or
already receiving ADT
93 Zoledronic acid + ADT vs placebo + ADT 12 months Increased LS BMD with zoledronic acid in those receiving ADT for < 1 year (+5.12% vs −3.13%
with placebo, p = 0.0029) and in those receiving ADT for more than 2 years (+4.82% vs +0.99%
with placebo, p = 0.0013)
2009 [66] Non metastatic PC 1468 Denosumab + ADT vs placebo + ADT 2 years Significant increase in LS BMD by 5.6% in denosumab arm vs 1.0% reduction in placebo arm
(p < 0.001). Denosumab reduced new vertebral fractures (1% vs 3.9%) and significantly reduced
BTM levels vs placebo
2011 [67] ADT in patients with PC and
osteoporosis
234 Denosumab + ADT vs alendronic acid + ADT 2 years Denosumab was superior to alendronic acid in improvement of LS BMD (+5.6% vs +1.1%).
2013 [68] ADT for 2–3 years and OP 104 Risedronate + ADT vs placebo + ADT 2 years Decreased LS BMD in both groups, no significant difference between groups
2013 [69] Localised PC 186 Alendronic acid + ADT vs placebo + ADT 12 months Significant increase in LS BMD with alendronic acid (+1.7% and −1.9% with placebo,
p < 0.0001)
In the above studies, significant reductions in BTMs were observed following administration of bone targeted agents Abbreviations: PC: prostate cancer; BM: bone metastasis; MAB: maximum androgen blockade; ADT:
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6. Management of CTIBL in prostate cancer
6.1. Patient and clinician education
Evidence suggests that men with PC receiving ADT often lack basic
osteoporosis knowledge and do not actively seek to take measures to
optimise their bone health [44]. Provision of individualised, patient-
centred information can improve knowledge and engagement with
appropriate lifestyle modifications. Published surveys of urologists and
oncologists have found that clinicians lack confidence in providing self-
management advice to patients to optimise bone health, and do not feel
able to effectively manage men who are identified as having abnormal
BMD [45,46]. We recommend this is addressed by clinicians following
Figs. 3 and 4 of this guidance which will be made available as a simple
downloadable guide.
6.2. Lifestyle factors
Both smoking and excessive alcohol intake are associated with
lower BMD in men with PC, and should be avoided [47]. It has been
demonstrated that exercise improves muscular strength, cardior-
espiratory fitness, lean body mass, fatigue, and quality of life in men
receiving treatment for PC [48]. NICE Clinical Guideline 131 [49] for
PC recommends that all men starting or having ADT should be offered
supervised resistance and aerobic exercise at least twice a week for
12 weeks. Further advice is provided by many organisations, including
the Royal Osteoporosis Society in the UK [50], the European Society of
Medical Oncology (ESMO) [51] and a compendium of EU-specific re-
ports [52].
6.3. The role of calcium and vitamin D
Daily calcium intake (DCI) is inadequate in the majority of older
men with PC [53]. The NOGG recommends a DCI of 700–1200 mg, if
possible through dietary intake with supplements if needed. DCI may be
calculated using an online tool (http://www.cgem.ed.ac.uk/research/
rheumatological/calcium-calculator).
Optimal bone health requires vitamin D (serum 25-hydroxyvitamin
D 25-OHD) levels of at least 50 nmol/L, and levels below 30 nmol/L
significantly increase the likelihood of bone disease [54]. Vitamin D
deficiency affects more than a quarter of older men, with up to three
quarters found to have insufficiency (25–50 nmol/L). NOGG re-
commends vitamin D supplementation with 800 IU daily in all men
aged over 50 at increased risk of fracture [55].
6.4. Bone protective agents
In randomised studies (Table 1) [56–69], bisphosphonates including
pamidronate, neridronate, risedronate, zoledronate and alendronate
have been shown to be effective in the prevention of BMD loss asso-
ciated with ADT at the lumbar spine (LS), femoral neck and total hip,
with accompanying significant reduction in BTMs.
However, bisphosphonate studies to date have had important lim-
itations including small patient numbers, heterogeneous populations,
variation in type and frequency of bisphosphonate administration, and
varying follow-up schedules. Importantly, no study has been suffi-
ciently powered to detect differences in fracture incidence, though a
meta-analysis of 15 randomised studies including 2,634 patients re-
ceiving ADT showed that treatment with bisphosphonates prevented
fracture (RR 0.8, 95% CI 0.69–0.94, p = 0.005)[70]. Most studies that
compared zoledronic acid with placebo used a 4 mg dose administered
3-monthly, a higher dose than the 5 mg infused annually for the
treatment of osteoporosis. It is unlikely that large, prospective, rando-
mised bisphosphonate trials for prevention of bone loss and reduction
of fracture rate in men receiving ADT will be carried out and no bi-
sphosphonate is currently approved for this specific purpose. However,
it seems reasonable to use bisphosphonates in men with PC under the
same rationale as they are used to manage other forms of osteoporotic
bone loss.
Larger randomised studies have been performed for denosumab in
men receiving ADT (details in Table 1). In a placebo-controlled study,
denosumab significantly increased BMD and reduced incidence of new
vertebral fractures [66]. In a randomised study in Italy, France and
Switzerland comparing denosumab with alendronate [67], denosumab
was superior in terms of improved LS BMD after 2 years. Although no
significant difference was observed in fracture rate, on the basis of these
results, denosumab has been authorised by the European Medicines
Authority for use in the prevention of CTIBL associated with ADT.
However, given that no significant difference if fracture rate has been
observed, it should be noted that there are differences in both cost and
side-effect profiles between denosumab and alendronate (and other
bisphosphonates) and, as with all bone-targeted agents, the choice of
agent will depend on patient need and local practice.
Bisphosphonates and denosumab are associated with similar ad-
verse effects, the most serious of which is osteonecrosis of the jaw
(ONJ). Studies of denosumab in both metastatic PC and non-metastatic
CRPC reported ONJ incidence of ≤5% [71,72]. Similarly, the fre-
quency of ONJ with bisphosphonate use in men with PC is 1–2% [72].
Importantly, these are based on doses used in metastatic bone disease
(4 mg zoledronic acid or 120 mg denosumab every 4 weeks). With
lower doses, the incidence in osteoporosis patients is substantially
lower, estimated at between 0.001% and 0.01% [73]. Both denosumab
and bisphosphonates are associated with an increased risk of hypo-
calcaemia, but when denosumab was given twice yearly to men with PC
on ADT, the incidence of hypocalcaemia was less than 1% [66].
Other pharmacological treatments for osteoporosis (including the
selective oestrogen receptor modulators raloxifene and toremifene) are
not currently recommended to prevent bone loss in PC patients re-
ceiving ADT. Teriparatide (recombinant PTH) is contraindicated in
patients with metastatic bone disease and in those who have received
prior radiotherapy.
Where patients with metastatic prostate cancer are already re-
ceiving anti-resorptive therapy for the management of their metastatic
disease (usually at higher doses than required for prevention of osteo-
porosis), there is clearly no benefit from further bone health mon-
itoring, as patients will already be receiving the appropriate therapy to
prevent/treat bone loss.
7. Fracture risk assessment and interventions
Risk assessment tools are available to determine the risk of fragility
fracture for individual patients. Additional clinical risk factors con-
tribute to fracture risk, at least partially independently of BMD (indeed
most fractures occur in individuals subsequently found to have non-
osteoporotic BMD). The two most frequently used tools are the Fracture
Risk Assessment Tool (FRAX® available at https://www.sheffield.ac.uk/
FRAX), which calculates 10 year probability of fracture and, QFracture
(https://qfracture.org) in the UK only, which can calculate 1–10 year
incidence of fracture. Both tools estimate the risk of hip fracture alone
and other major osteoporotic fractures (hip, clinical spine, wrist or
humerus). Unlike QFracture, FRAX® may be used with or without BMD.
In contrast to FRAX®, there are currently no published intervention
thresholds using the QFracture tool. Neither has been specifically de-
veloped for use in men with PC.
7.1. Frax®
FRAX® is based on primary data from 12 prospectively studied po-
pulation-based international cohorts, comprising more than 60,000
individuals and 5000 incident fractures, with subsequent external va-
lidation in cohorts comprising 230,486 individuals. Although men
comprised only 25% of the original FRAX® cohorts, current evidence
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suggests that the risk is the same in both sexes and the tool has been
shown to be of predictive value in both male and mixed gender cohorts
[74].
FRAX® does not require specialist knowledge and can be performed
in general practice or outpatient settings. It incorporates a relatively
small number of clinical risk factors (Fig. 1). Anticancer treatments are
not currently included as a specific risk factor. FRAX® computes frac-
ture probability taking both the risk of fracture and risk of death into
account, important because some risk factors affect both. FRAX® is used
in an increasing number of guidelines worldwide. In addition to pro-
viding an estimate of risk, the FRAX® website in some country models
has a link to national guidance for the management of osteoporosis
(such as the UK National Osteoporosis Guideline Group in the UK).
FRAX has recently been shown to be predictive of falls in elderly
men [75]. This is particularly significant in older men receiving ADT,
which alters body composition. As well as increasing the risk of falls,
sarcopenia also decreases rehabilitation potential in the post-fall setting
[76].
7.2. FRAX® and ADT
The inclusion of ADT as a new, specific risk variable within FRAX®
would require sufficient evidence that ADT is associated with fracture
risk independently of the risk variables already included, particularly
BMD. Current evidence suggests that this may not be the case [77,78].
A conservative assumption, therefore, would be that the modification of
fracture risk by ADT is captured almost completely by its impact on
BMD. The secondary osteoporosis variable in FRAX® already serves this
function and so should be ticked when patients receive ADT. This
variable contains a number of risk factors that have been shown to be
associated with fracture risk (RR 1.3–1.7) but with little or no evidence
that this risk is truly independent of BMD. Thus, if and when BMD is
entered to the calculation, no further weight is accorded to the presence
of this risk factor. As for any clinical prediction tool, interpretation
should be tempered by additional information of clinical significance;
such as a high falls risk, multiple prior fractures, immobility and severe
rheumatoid arthritis.
In addition to ADT, men with newly diagnosed metastatic prostate
cancer may also receive additional systemic therapies, which are given
with concurrent glucocorticoids. Docetaxel chemotherapy involves
daily prednisolone and pre-treatment dexamethasone, for up to
18 weeks. Abiraterone acetate may also be given along with a daily
dose of prednisolone for up to 2 years. All men undergoing prolonged
periods of exposure to medium/high doses of glucocorticoids have a
greater risk of fracture, which is reflected in its inclusion in the FRAX®
risk factors.
7.3. Intervention thresholds
Approaches used to set intervention thresholds [79,80] depend on
local factors such as reimbursement policies, health economic assess-
ment, willingness to pay for health care in osteoporosis and access to
DXA. Most recommendations for intervention thresholds in osteo-
porosis are based on postmenopausal osteoporosis where there is an
Fig. 1. The UK FRAX® tool. Screenshot showing a FRAX®calculation of major fracture and hip fracture probability in a man aged 70 years with secondary osteo-
porosis (e.g. prostate cancer on ADT). Note that, because there is no BMD measurement included, the secondary osteoporosis factor has been checked as ‘Yes’ in
recognition of the patient being on ADT. If a BMD measurement was included, the FRAX® risk calculation would take no account of whether the secondary
osteoporosis box is checked or not as the BMD takes precedence.
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established evidence base, but NOGG has included the management of
male osteoporosis in their most recent guidance [55]. Since it would be
difficult to justify a different (i.e. lower) intervention threshold in men,
it is logical to apply the same thresholds in men with PC. Thus, men
with probabilities at or above the upper threshold (Fig. 2) should be
offered treatment.
As current evidence suggests that fracture risk in ADT users is BMD-
dependent, it is reasonable to suggest that BMD should be included in
the risk calculation by FRAX® for all PC patients, wherever this is
feasible. Where access to BMD is limited, FRAX® should be performed
and BMD measurements targeted to those men with FRAX® prob-
abilities, calculated without BMD (but selecting the secondary osteo-
porosis box to recognise ADT), lying close to the intervention threshold
(for example, the amber area on the chart available at https://www.
sheffield.ac.uk/NOGG/result-nobmd.html?).
Fig. 2. NOGG intervention thresholds. The thresholds depicted by the lines between the green and red areas above are the 10-year probabilities of a major os-
teoporotic fracture (left graph) or hip fracture (right graph) in women with a previous fracture. Applying the same criteria to men with PC, treatment should be
strongly considered in those with fracture probabilities at or above the threshold. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 3. Algorithm for assessment of bone health in prostate cancer patients receiving ADT. Note regarding patients with mCRPC: Around 80% mCRPC patients
develop bone metastases. In patients with bone metastases from CRPC at high risk for clinically significant SREs, ESMO guidelines recommend denosumab or
zoledronate at doses higher than those required for protection against CTIBL alone. However, where mCRPC patients do not already receive bone protection for
prevention of metastatic morbidity, in view of emerging data referred to in Section 3, it is strongly recommended that all such patients should be considered for bone
protection to prevent osteoporotic fragility fractures.
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7.4. Further assessment prior to treatment
Men with a previous fracture and/or who are found to be osteo-
porotic should have further investigations to exclude other causes of
secondary osteoporosis, as treatment of the latter (e.g. malabsorption or
liver disease) forms part of overall management. This may be best
achieved by referral to appropriate services (metabolic bone/rheuma-
tology/endocrinology).
7.5. Dosing regimens
NOGG recommends oral bisphosphonates such as alendronate
(10 mg daily) or risedronate (5 mg daily) for osteoporosis in men, re-
flecting the licensed doses. In clinical practice, however, the majority of
men receive once weekly oral bisphosphonates (alendronic acid 70 mg
or risedronate sodium 35 mg) as used in women with postmenopausal
osteoporosis. Oral therapy can often be initiated by the patient’s GP
following assessment of fracture risk. Where oral therapy is not feasible
or tolerated, intravenous zoledronic acid may be used (5 mg once
yearly), or denosumab can be given subcutaneously at a dose of 60 mg
once every 6 months.
7.6. Reassessment of fracture risk
Fracture risk reassessment should be undertaken when there is a
change in systemic therapy or a change in risk factor profile (e.g.
commencing glucocorticoids, incident fracture, development of other
cause of secondary osteoporosis etc). In men on ADT whose fracture
risk lies below but close to the intervention threshold, a FRAX re-
assessment (including a repeat BMD) should be undertaken after
12–18 months. All men who have been on ADT for 5 years should be
reassessed even if they were not deemed at risk on baseline FRAX®.
In those on bone protective therapy, reassessment should be un-
dertaken in 3 years for those receiving intravenous zoledronate an-
nually, or 5 years for oral bisphosphonate use. Denosumab use should
also be reviewed at 5 years but not discontinued without review in a
Fig. 4. Guidance for clinicians. The following guidance is given for management of bone health in patients with prostate cancer starting ADT or for patients already
receiving ADT who have not previously had a bone health assessment.




Maintenance of bone health is increasingly important in patients
with PC where, even in advanced disease, survival is now typically
several years. The range and numbers of lines of treatment men receive,
especially in the advanced setting, is increasing and many have impacts
on the skeleton. It is critical to embed consideration of bone health and
its optimisation throughout the patient journey.
9. Recommendations
The clinical guidance summarised in Figs. 3 and 4 should be fol-
lowed for all men commencing ADT and for all men currently on ADT
who have not had previous assessment of fracture risk. It is important
that all care pathways, although they may vary locally, should identify
at an early stage who in the care pathway carries responsibility for bone
health monitoring and treatment. We recommend that these guidelines
should be available as a quick reference guide, including a brief sum-
mary and algorithm, as an electronic download for use in routine
practice.
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